Novo Nordisk A/S-BNONOF
13F holders, Q4 2025 (December 31)2holders −1
0new positions
2sold out
$51.05avg. 13F price*
At the end of Q4 2025, 2 institutions reported holding Novo Nordisk A/S-B (NONOF) in their 13F filings, down 1 from Q3 2025. 0 opened new positions and 2 sold out. The largest holders were Atlas Capital Advisors Inc. ($266K) and Steigerwald, Gordon & Koch Inc. ($3K).
- Company
- Novo Nordisk A/S-B
- CUSIP
- K72807140
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 2 | $1.1M |
All 13F filers, Q3 2025 → Q4 2025: 20,681 shares sold, net −20,681 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Atlas Capital Advisors Inc. | 0.03% | — | 5,218 | $266K |
| Steigerwald, Gordon & Koch Inc. | 0.00% | No change | 60 | $3K |
"% of holder's portfolio" is NONOF's weight in each manager's 13F, not the share of Novo Nordisk A/S-B the manager owns.